10 Best Debt Free Mid Cap Stocks to Buy Now
Debt-free mid-cap stocks currently offer compelling investment opportunities, especially in today's high-interest-rate environment.
Nuvalent Inc. (NUVL)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deerfield Management James E. Flynn | 17,991,024 | $1,408,337,359 | -11% | 26.67% |
| 2. | Perceptive Advisors Joseph Edelman | 2,619,977 | $205,091,800 | -13% | 5.65% |
| 3. | Commodore Capital Egen Atkinson And Michael Kramarz | 1,621,600 | $126,938,848 | +73% | 9.3% |
| 4. | Woodline Partners Michael Rockefeller And Karl Kroeker | 1,204,927 | $94,321,686 | +1% | 0.63% |
| 5. | Boxer Capital Aaron Davis And Christopher Fuglesang | 1,120,192 | $87,688,630 | 7.46% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $33.50 | 650,000 | Large Shareholder, Director, Other | 650,000 | 2022-11-03 | Filing | |
| $33.50 | 149,253 | Director | 3,577,267 | 2022-11-03 | Filing | |
| $17.00 | 735,000 | Director | 3,428,014 | 2021-08-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $70.73 | 488 | 249,062 | 2025-04-15 | Filing | ||
| $70.05 | 4,465 | 249,550 | 2025-04-15 | Filing | ||
| $69.05 | 11,060 | 254,015 | 2025-04-15 | Filing | ||
| $68.31 | 10,987 | 265,075 | 2025-04-15 | Filing | ||
| $73.83 | 900 | 48,034 | 2025-03-27 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 53,026 | $3,760,589 | 0% | |
| 2. | 3,000 | $212,760 | 0.06% | |
| 3. | 1,654 | $117,302 | 0% | |
| 4. | 350 | $24,822 | 0.02% | |
| 5. | 141 | $10,000 | 0% |
News See All
10 Best Mid Cap Biotech Stocks to Buy
On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC's 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.
10 Mid-Cap Stocks Insiders Are Selling Recently
Why should investors analyze insider trading activity? Insiders, or people in high positions within a company—such as executives and directors—can have crucial insights into the company’s strategic...
Billionaire Joseph Edelman's Top 10 Long-Term Stock Picks
Joseph Edelman is a renowned figure in the investment world, recognized for his expertise in biotechnology and healthcare investing.
10 Largest Biotech Hedge Funds and Their Top Stock Picks
The ability to successfully make money through investment requires deep thinking and analysis.
10 Worst Cancer Stocks To Buy Now According to Short Sellers
Cancer is the second leading cause of death globally, just behind cardiovascular disease, making oncology one of the largest sectors in the life sciences.
13 Best Short Squeeze Stocks To Buy Now
In this piece, we will take a look at the 13 best short squeeze stocks to buy now.
12 Small-Cap Stocks With Insider Buying
Insider buying refers to a company's officers, directors, or major shareholders purchasing shares of their own company's stock.
12 Best Small-Cap Healthcare Stocks To Buy Now
Macroeconomic headwinds and recessionary concerns will not weaken healthcare deals next year after the market experienced resilient mergers and acquisitions in 2022.
Billionaire Hedge Funds
